Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rocket Doctor AIAIRDF +0.40%29 Net Cash per Share is $-0.03 as of Mar. 2026. GuruFocus rates AIRDF with a GF Score™ of 29/100. The stock has 7 warning signs investors should review. Among 145 Healthcare Providers & Services companies, Rocket Doctor AI ranks worse than 689654.48% on this metric.
The historical rank and industry rank for Rocket Doctor AI's Net Cash per Share or its related term are showing as below:
During the past 7 years, the highest Price-to-Net-Cash Ratio of Rocket Doctor AI was 820.00. The lowest was 21.50. And the median was 74.00.
AIRDF's Price-to-Net-Cash is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 7.79 * Ranked among companies with meaningful Price-to-Net-Cash only.
Rocket Doctor AI (OTCPK:AIRDF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Rocket Doctor AI Net Cash per Share Related Terms
Rocket Doctor AI Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Rocket Doctor AI's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIRDF vs VEEV, BTSG, HQY: Net Cash per Share Comparison
For the Health Information Services subindustry, Rocket Doctor AI's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rocket Doctor AI Price-to-Net-Cash vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Rocket Doctor AI's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Rocket Doctor AI's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Rocket Doctor AI's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rocket Doctor AI (AIRDF) has a Net Cash per Share of $-0.03 as of Mar. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Rocket Doctor AI and its competitors. Over the past decade, Rocket Doctor AI's Net Cash per Share has ranged from 21.50 to 820.00. According to the industry distribution chart, Rocket Doctor AI ranks #999999 out of 145 companies in the Healthcare Providers & Services industry.
Is Rocket Doctor AI's Net Cash per Share too high?
Rocket Doctor AI's current Net Cash per Share is $-0.03. Over the past 10 years, this metric has ranged from a low of 21.50 to a high of 820.00. Based on the distribution chart, Rocket Doctor AI ranks #999999 out of 145 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Rocket Doctor AI has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Rocket Doctor AI's Net Cash per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Rocket Doctor AI ranks #999999 out of 145 companies for Net Cash per Share. This places Rocket Doctor AI in the lower half of its industry. The industry median Net Cash per Share is 7.79. Historically, Rocket Doctor AI's own Net Cash per Share has ranged from 21.50 to 820.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Healthcare Providers & Services company?
The median Net Cash per Share among Healthcare Providers & Services companies is 7.79, based on 145 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Rocket Doctor AI and its competitors. For the Healthcare Providers & Services industry, the median Net Cash per Share is 7.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rocket Doctor AI's current Net Cash per Share is $-0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rocket Doctor AI stock overvalued right now?
Rocket Doctor AI (AIRDF) has a current Net Cash per Share of $-0.03. The current Net Cash per Share is $-0.03. Rocket Doctor AI's overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Rocket Doctor AI (AIRDF), the current Net Cash per Share is $-0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rocket Doctor AI Inc delivers physician-built, AI-powered solutions designed to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of the company's proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians world-wide. Alongside the GLM and its AI-powered digital health platform and marketplace. The group empowers over 300 MDs to provide care to more than 700,000 patients. Its proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices - improving efficiency, restoring autonomy to MDs, and expanding patient access to care.
29GF Score
Get the complete analysis for AIRDF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIRDF has been successfully added to your 
